Azoximer bromide-modulated immune response in aerobic vaginitis

Aim: to evaluate the efficacy of azoximer bromide along with a combined antimicrobial drug in treatment of patients with aerobic vaginitis (AV).Materials and Methods. There was conducted a prospective, randomized, parallel group study with enrolled 60 patients diagnosed with AV and 10 apparently hea...

Full description

Bibliographic Details
Main Authors: G. B. Dikke, V. V. Ostromenskii, Yu. G. Kucheryavaya
Format: Article
Language:Russian
Published: IRBIS LLC 2022-01-01
Series:Акушерство, гинекология и репродукция
Subjects:
Online Access:https://www.gynecology.su/jour/article/view/1181
_version_ 1797884082226462720
author G. B. Dikke
V. V. Ostromenskii
Yu. G. Kucheryavaya
author_facet G. B. Dikke
V. V. Ostromenskii
Yu. G. Kucheryavaya
author_sort G. B. Dikke
collection DOAJ
description Aim: to evaluate the efficacy of azoximer bromide along with a combined antimicrobial drug in treatment of patients with aerobic vaginitis (AV).Materials and Methods. There was conducted a prospective, randomized, parallel group study with enrolled 60 patients diagnosed with AV and 10 apparently healthy women (control group III). Group I (n = 30) received azoximer bromide (10 vaginal insertion according to the scheme, course of 10 days) and a combined antimicrobial drug, while Group II (n = 30) received only antimicrobial drug (course of 10 days). Microscopy of vaginal discharge smears, polymerase chain reaction method was used, detection of cytokines – interleukins (IL) and tumor necrosis factor-alpha (TNF-α) in vaginal washings was performed by ELISA. The study of neutrophil extracellular traps (NETs) was performed by ELISA, and DNA-containing strands ejected by neutrophils were determined by fluorescence method.Results. Recovery from disease was found in 100 % (30/30) and 86.7 % (26/30) in group I and group II, respectively. After treatment, serum level of IL-8 was revealed to decline in group I from 35.2 to 5.5 pg/ml (p = 0.05), in group II – from 33.4 to 5.3 pg/ml (p = 0.04), also not differ (p > 0.05) from the control values (5.2 pg/ml). The level of IL-1β also decreased after treatment in group I from 51.5 to 15.1 pg/ml (p = 0.002), in group II – from 57.9 to 20.1 pg/ml (p = 0.03), which also did not differ (p > 0.05) from the control values (16.7 pg/ml). The IL-10 level in both main groups decreased slightly (from 0.26 and 0.24 to 0.16 pg/ml in both groups), which was higher by 1.8-fold than in the control group (0.09 pg/ml; p < 0.001). The number of ejected NETs in both main groups decreased significantly after treatment, reaching control level. No side effects were observed, compliance and acceptability were 100 % in both groups. The frequency of AV relapses within 3 months was observed in 3.3 % (1/30) and 14.3 % (4/28) patients, after 6 months – in 14.3 % (4/28) and in 20.0 % (5/25) patients in groups I and II, respectively. Using the logit regression model, demonstrated that AV relapse might occur with a 50 %-probability at TNF-α level < 0.1 pg/ml after treatment (sensitivity – 67 %, specificity – 79 %). The risk of relapses in group I, in contrast to group II, showed a downward trend.Conclusions. The use of azoximer bromide and a combined broad-spectrum antimicrobial drug is effective in AV treatment, exerts a modulating effect on immune response parameters contributes to lowering relapse rate.
first_indexed 2024-04-10T04:01:57Z
format Article
id doaj.art-b2231623d9b94c6ba1b355018a9c8f10
institution Directory Open Access Journal
issn 2313-7347
2500-3194
language Russian
last_indexed 2024-04-10T04:01:57Z
publishDate 2022-01-01
publisher IRBIS LLC
record_format Article
series Акушерство, гинекология и репродукция
spelling doaj.art-b2231623d9b94c6ba1b355018a9c8f102023-03-13T07:09:51ZrusIRBIS LLCАкушерство, гинекология и репродукция2313-73472500-31942022-01-0115666968410.17749/2313-7347/ob.gyn.rep.2021.271691Azoximer bromide-modulated immune response in aerobic vaginitisG. B. Dikke0V. V. Ostromenskii1Yu. G. Kucheryavaya2Inozemtsev Academy of Medical EducationInozemtsev Academy of Medical EducationInozemtsev Academy of Medical EducationAim: to evaluate the efficacy of azoximer bromide along with a combined antimicrobial drug in treatment of patients with aerobic vaginitis (AV).Materials and Methods. There was conducted a prospective, randomized, parallel group study with enrolled 60 patients diagnosed with AV and 10 apparently healthy women (control group III). Group I (n = 30) received azoximer bromide (10 vaginal insertion according to the scheme, course of 10 days) and a combined antimicrobial drug, while Group II (n = 30) received only antimicrobial drug (course of 10 days). Microscopy of vaginal discharge smears, polymerase chain reaction method was used, detection of cytokines – interleukins (IL) and tumor necrosis factor-alpha (TNF-α) in vaginal washings was performed by ELISA. The study of neutrophil extracellular traps (NETs) was performed by ELISA, and DNA-containing strands ejected by neutrophils were determined by fluorescence method.Results. Recovery from disease was found in 100 % (30/30) and 86.7 % (26/30) in group I and group II, respectively. After treatment, serum level of IL-8 was revealed to decline in group I from 35.2 to 5.5 pg/ml (p = 0.05), in group II – from 33.4 to 5.3 pg/ml (p = 0.04), also not differ (p > 0.05) from the control values (5.2 pg/ml). The level of IL-1β also decreased after treatment in group I from 51.5 to 15.1 pg/ml (p = 0.002), in group II – from 57.9 to 20.1 pg/ml (p = 0.03), which also did not differ (p > 0.05) from the control values (16.7 pg/ml). The IL-10 level in both main groups decreased slightly (from 0.26 and 0.24 to 0.16 pg/ml in both groups), which was higher by 1.8-fold than in the control group (0.09 pg/ml; p < 0.001). The number of ejected NETs in both main groups decreased significantly after treatment, reaching control level. No side effects were observed, compliance and acceptability were 100 % in both groups. The frequency of AV relapses within 3 months was observed in 3.3 % (1/30) and 14.3 % (4/28) patients, after 6 months – in 14.3 % (4/28) and in 20.0 % (5/25) patients in groups I and II, respectively. Using the logit regression model, demonstrated that AV relapse might occur with a 50 %-probability at TNF-α level < 0.1 pg/ml after treatment (sensitivity – 67 %, specificity – 79 %). The risk of relapses in group I, in contrast to group II, showed a downward trend.Conclusions. The use of azoximer bromide and a combined broad-spectrum antimicrobial drug is effective in AV treatment, exerts a modulating effect on immune response parameters contributes to lowering relapse rate.https://www.gynecology.su/jour/article/view/1181aerobic vaginitisavcytokinesneutrophil extracellular trapsnetsazoximer bromidepolyoxidonium
spellingShingle G. B. Dikke
V. V. Ostromenskii
Yu. G. Kucheryavaya
Azoximer bromide-modulated immune response in aerobic vaginitis
Акушерство, гинекология и репродукция
aerobic vaginitis
av
cytokines
neutrophil extracellular traps
nets
azoximer bromide
polyoxidonium
title Azoximer bromide-modulated immune response in aerobic vaginitis
title_full Azoximer bromide-modulated immune response in aerobic vaginitis
title_fullStr Azoximer bromide-modulated immune response in aerobic vaginitis
title_full_unstemmed Azoximer bromide-modulated immune response in aerobic vaginitis
title_short Azoximer bromide-modulated immune response in aerobic vaginitis
title_sort azoximer bromide modulated immune response in aerobic vaginitis
topic aerobic vaginitis
av
cytokines
neutrophil extracellular traps
nets
azoximer bromide
polyoxidonium
url https://www.gynecology.su/jour/article/view/1181
work_keys_str_mv AT gbdikke azoximerbromidemodulatedimmuneresponseinaerobicvaginitis
AT vvostromenskii azoximerbromidemodulatedimmuneresponseinaerobicvaginitis
AT yugkucheryavaya azoximerbromidemodulatedimmuneresponseinaerobicvaginitis